AFZANNA 40 TABLET 28'S

Patients should not donate blood while taking AFZANNA 40 TABLET 28'S, as the medication can be harmful to the recipient. It is important to inform your healthcare provider if you plan to donate blood, as they may advise you to wait until after you have finished treatment.

The ability to work or go to school while taking AFZANNA 40 TABLET 28'S will depend on your individual condition and response to treatment. Some patients may experience fatigue or other side effects that can impact their ability to perform daily activities.

There is limited information on the effects of AFZANNA 40 TABLET 28'S on fertility. However, it is important to inform your healthcare provider if you are trying to conceive, as some cancer treatments can affect fertility.

If you have a history of heart problems, it is important to discuss the potential risks and benefits of using AFZANNA 40 TABLET 28'S with your healthcare provider before starting treatment. This medication can cause cardiac problems, and your healthcare provider may need to monitor you closely during treatment.

AFZANNA 40 TABLET 28'S is sometimes used in combination with other cancer treatments, such as chemotherapy or immunotherapy. However, the safety and effectiveness of these combinations will depend on your individual condition and treatment plan.

There is NULL interaction of AFZANNA 40 TABLET 28'S with other drugs

Follow all instructions and dosing recommendations provided by your healthcare provider. Do not take more or less of the medication than prescribed. Report any new or worsening symptoms to your healthcare provider immediately, especially if they relate to your lungs, eyes, skin, liver, kidneys, heart, or bleeding. Stay well-hydrated and report any signs or symptoms of dehydration to your healthcare provider immediately, especially if you experience severe diarrhea. Women should avoid pregnancy or breastfeeding. Reproductive-age women should use effective birth control during the treatment and for at least two weeks after your last dose. Patients should report any signs or symptoms of dehydration, such as dry mouth or decreased urination, to a healthcare provider immediately.

AFATINIB DIMALEATE is molecule/combination used for making AFZANNA 40 TABLET 28'S.

AFZANNA 40 TABLET 28'S is prescribed for {Oncology}.